ArticleAsian Pacific journal of cancer prevention : APJCP2026
The Prognostic Impact of Supraclavicular Lymph Node Metastases in Lung Cancer: Do We Need a Modification of the Current Staging System?
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe management of Stage IIIB non-small-cell lung cancer (NSCLC) is complex. The current staging system does not distinguish between ipsilateral and contralateral supraclavicular lymph node involvement, although this distinction may impact prognosis. This study investigates the differences in prognosis between these two presentations of N3 disease.
methodsThis study presents a retrospective analysis of 113 patients diagnosed with Stage IIIB NSCLC who had supraclavicular lymph node metastases and underwent chemoradiation therapy. Patients were categorized based on whether their supraclavicular involvement was ipsilateral or contralateral to the primary lung tumor. Survival outcomes were calculated and correlated with various factors.
resultsPatients with ipsilateral supraclavicular metastases had a median progression-free survival of 12 months, compared to 9 months for those with contralateral involvement. The median overall survival for the two groups was 17 months and 14 months, respectively. Poorer survival outcomes were associated with contralateral nodal involvement, older age, poor performance status, and exclusive radiotherapy treatment.
conclusionContralateral supraclavicular metastases are associated with a worse prognosis compared to ipsilateral involvement in Stage IIIB NSCLC. These findings suggest a need to reevaluate their classification within current staging systems and to consider systemic treatment for these high-risk patients. Phase III randomized controlled trials are needed to validate this observation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.